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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver a scientific opinion on vitamin D2 mushroom powder as a
novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is an ingredient produced from
Agaricus bisporus mushrooms that have been exposed to ultraviolet (UV) light to induce the
conversion of provitamin D2 (ergosterol) to vitamin D2 (ergocalciferol). The NF contains concentrations
of vitamin D provided by vitamin D2 in the ranges of 1,000–1,300 lg/g. The information provided on
the manufacturing process, composition and specifications of the NF does not raise safety concerns.
The applicant intends to add the NF in a variety of foods and beverages, including food for special
medical purposes and food supplements. The target population is the general population except for
food supplements, for which the target population is individuals above seven months of age. The
Panel concludes that the NF, used as an ingredient, is safe for the general population at the proposed
condition of use in foods and beverages and that the NF used as a food supplement, is safe for
individuals above 1 year. The Panel, however, notes that the UL for infants aged 0–6 months may be
exceeded in high consumers of infant formula (IF) and/or follow-on formula (FoF) that may also be
high consumers of foods fortified with the NF and for infants aged 7–12 months consuming a daily
vitamin D oral supplementation of 10 lg. However, the Panel considers this scenario unlikely as
complementary feeding in high consumers of IF and/or FoF may be limited. Furthermore, the
combined consumption of vitamin D via fortified foods and supplements does not specifically concern
this NF application. The Panel concludes that the NF is safe under the proposed conditions of use for
the proposed target populations.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
On 17 July 2018, the company Oakshire Naturals, LP submitted a request to the European
Commission in accordance with Article 10 of Regulation (EU) No 2015/22831 to place vitamin D2
mushroom powder on the Union market as a novel food.
The novel food (vitamin D2 mushroom powder) is intended for use in foods, beverages and food
supplements. The target population is the general population with the exception of food supplements,
which are intended for the general population upwards of 7 months of age.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on vitamin D2 mushroom powder as a
novel food.
1.2. Additional information on existing evaluations and authorisations
Controlled ultraviolet (UV) irradiation is used to enhance the concentration of vitamin D2 in
mushrooms. Commercially grown UV-treated Agaricus bisporus mushrooms are approved in the
European Union (EU) market as a novel food (NF) since 2016 (FSAI, 2017). No safety concerns
associated with the consumption of commercially cultivated mushrooms subjected to controlled UV
light were raised by the competent authorities of EU Member States.
UV irradiation technique to enhance the content of vitamin D has been used in other approved
novel foods evaluated by EFSA: UV-treated baker’s yeast (Saccharomyces cerevisiae) (EFSA NDA
Panel, 2014), UV-treated bread (EFSA NDA Panel, 2015) and UV-treated milk (EFSA NDA Panel,
2016c). All of them are currently under the Commission Implementing Regulation (EU) 2017/2470 of
20 December 2017 establishing the Union list of novel foods.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following EFSA requests for supplementary information.
During the assessment, the Panel identified additional data which were not included in the
application (Gordon et al., 2008; Gallo et al., 2013; Cashman et al., 2016).
The applicant also provided a comprehensive literature search conducted in several databases to
identify issues of potential safety relevance for vitamin D2 mushroom powder (Annex V of the dossier).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24692.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application (EFSA NDA Panel, 2016a). As indicated
in this guidance, it is the duty of the applicant to provide all of the available (proprietary, confidential and
published) scientific data, including both data in favour and not in favour to supporting the safety of the
proposed NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. Data claimed to be proprietary by the applicant include: Raw
materials and processing aids (Annex I to the dossier), Certificates of Analysis and batch data (Annex
II to the dossier) and Stability reports (Annex III to the dossier).
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/2011
of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the
Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1.
2 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientific Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under
the proposed conditions of use and is not an assessment of the efficacy of vitamin D2 mushroom
powder with regard to any claimed benefit.
3. Assessment
3.1. Introduction
The NF which is the subject of the application is vitamin D2 mushroom powder as a novel food as
defined in article 3 of the NF Regulation 2015/2283. The NF falls under the category (ii) ‘food
consisting of, isolated from or produced from microorganisms, fungi or algae’.
The NF contains concentrations of vitamin D as vitamin D2 in the range of 1,000–1,300 lg/g.
The applicant intends to market the NF as an ingredient in foods and beverages for consumption
by the general population. Vitamin D2 mushroom powder food supplements are intended for
individuals above 7 months of age.
3.2. Identity of the NF
The NF is a whole mushroom powder containing vitamin D2 (ergocalciferol) induced by UV
treatment.
According to the applicant, this vitamin D2 whole mushroom powder is a slightly brown or tan
granular powder made from homogenised Agaricus bisporus mushrooms that have been exposed to
UV light to induce the conversion of provitamin D2 (ergosterol) to vitamin D2 (ergocalciferol).
The product contains vitamin D2 with registered CAS number 50-14-6 and its IUPAC 5Z,7E,22E)-
(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol. The molecular formula of vitamin D2 is C28H44O.
The source of the NF is the fungus Agaricus bisporus as listed in the Index fungorum (http://www.
indexfungorum.org/names/names.asp). Various common synonyms for this mushroom are closed cap,
large – flat, common, cremini, button, cultivated, chestnut or portobello mushroom, depending on size,
shape, and colour of the mushroom.
3.3. Production process
The mushrooms used in the production of vitamin D2 mushroom powder are cultivated Agaricus
bisporus. The cultivation is in accordance with current Good Agricultural Practices (GAP) and all
facilities comply with Food Safety Modernization Act (FSMA) produce rules. The producer has a Hazard
Analysis Critical Control Points (HACCP) plan in place.
As a first step, the mushrooms are washed and homogenised in a mixing kettle to produce a
mushroom puree. The mushroom puree is transferred onto a shaker tray that passes under a UV
lamp. The slurry is then filtered, dried and ground, producing vitamin D2 mushroom powder.
The process conditions of the UV treatment, i.e. energy input and range of wavelength, have been
provided by the applicant, after request for additional information from EFSA.
Based on previous EFSA assessments on UV-treated novel foods (EFSA NDA Panel, 2014, 2015,
2016c) that are currently authorised, the Panel considers the specified parameters, including the range
of wavelength for the UV treatment, as being similar.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
The applicant provided product analysis of six independent batches of the NF (Table 1). The
applicant provided the certificate of analysis for each batch.
Safety of vitamin D2 mushroom powder
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2020;18(1):5948
The analytical method used by the applicant for vitamin D2 is validated in-house as well as by
sample exchange with two reference laboratories. Vitamin D2 is quantified using high-performance
liquid chromatography (HPLC) with UV detection and [3H]-vitamin D3 as the internal standard as
described in Phillips et al. (2011).
Another form of vitamin D described as vitamin D4 (22-dihydroergocalciferol) has been observed
and confirmed by HPLC in edible mushrooms in a compositional analysis by Phillips et al. (2012). To
account for the separation of vitamin D4 from the D3 internal standard, modified HPLC conditions as
described by Phillips et al. (2012) are applied by the applicant.
Upon an EFSA request, the applicant provided the chromatograms of 6 reported batches of the NF
showing the peaks for the different forms of vitamin D (vitamin D2, vitamin D3 internal standard and
vitamin D4). The analyses indicated that the concentrations of vitamin D4 in the NF are at
approximately 1/10th the concentration of vitamin D2.
The physical parameters particle size and appearance indicated that the six analysed batches of the
NF are a slightly brown or tan, granular powder that passes through an 80-mesh sieve.
Upon request of EFSA, the applicant provided full compositional information, including nutritional
composition, on 5 batches.
The applicant also provided analyses of chemical and microbiological contaminants of 6
independent batches of the NF (Tables 2 and 3). All investigated batches met the specifications (see
Section 3.5) regarding microbiological and chemical contaminants.
The chemical contaminants within the investigated batches of the NF, where applicable, were below
the limits specified in Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting
maximum levels (MLs) for certain contaminants in foodstuffs.3 For contaminants with maximum levels
in mushrooms (i.e. the source of the NF), specific MLs from the legislation were used (i.e. lead).
The results for arsenic, lead, mercury, and cadmium have been converted by the applicant to
equivalent wet weight values based on the moisture content of vitamin D2 mushroom powder (10%)
and of Agaricus bisporus mushrooms (approximately 90% (OECD, 2007)).
Table 1: Batch-to-batch analysis of six batches of the NF
Parameter Batch number and date of manufacture Method of analysis
Batch #1 Batch #2 Batch #3 Batch #4 Batch #5 Batch #6
Vitamin D2
(lg/g)
1,276.9 1,129.2 1,066.6 1,257.3 1,172.1 1,169.5 HPLC
Moisture (%) 4.39 3.24 5.07 4.77 3.39 4.87 AOAC 964.22
Ash (%) 6.12 4.87 4.80 6.40 6.28 5.71 AOAC 945.46
AOAC: Association of Official Analytical Chemists; HPLC: high-performance liquid chromatography.
Table 2: Analysis of chemical contaminants of 6 batches of the NF
Potential chemical
contaminants
Batch number and date of manufacture
Method of
analysis
Batch #1 Batch #2 Batch #3 Batch #4 Batch #5 Batch #6
Arsenic (mg/kg) 0.011* 0.011* 0.011* 0.011* 0.011* 0.011* USP 730
Lead (mg/kg) 0.006* 0.006* 0.006* 0.006* 0.006* 0.006*
Mercury (mg/kg) 0.004* 0.004* 0.004* 0.004* 0.004* 0.004*
Cadmium (mg/kg) 0.003* 0.003* 0.003* 0.003* 0.003* 0.003*
Aflatoxins (sum of
B1, B2, G1 and G2)
(lg/kg)
< 0.7 < 0.7 < 0.7 < 0.7 < 0.7 < 0.7 AOAC 994.08
AOAC: Association of Official Analytical Chemists; USP: United States Pharmacopeia.
*: Equivalent wet weight values calculated based on a 10% moisture content of vitamin D2 mushroom powder and a moisture
content of approximately 90% (OECD, 2007)] for Agaricus bisporus mushrooms Calculation = reported value 9 (1/9).
3 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:
02006R1881-20180319&from=EN [Consolidated]
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The applicant states that screenings for the presence of pesticides in batches of the NF are
conducted using internationally accepted methods (EN 15662/Canadian Food Inspection Agency (CFIA)
PMR-006).
The applicant conducted a multi-residue pesticide screen on a representative batch of vitamin D2
mushroom powder, and the full results were provided in the certificates of analysis in Annex II of the
application. None of the pesticides were detected (detection limit of < 0.005 mg/kg for all compounds,
with the exception of 2-(thiocyanomethylthio) benzothiazole (< 0.006 mg/kg), folpet (< 0.012 mg/kg)
and fenamiphos sulfone (< 0.013 mg/kg)). The Panel notes that those levels are below the EU
maximum residue levels for pesticides.4
Microbiological analyses for vitamin D2 mushroom powder are presented in Table 3.
The conversion of ergosterol into vitamin D2 with UV exposure is accompanied by photochemical
isomerisations resulting in photoisomers such as lumisterol and tachysterol (Havinga et al., 1960). Both
lumisterol and tachysterol are biologically inactive and known to be formed in the course of the
UV-induced conversion of epidermal 7-dehydrocholesterol into vitamin D3 (Holick et al., 1981).
The applicant, therefore, performed analyses to investigate the potential formation of these sterols
under the conditions of the UV treatment of the mushroom powder. The results of HPLC showed that,
apart from the intended vitamin D2, both tachysterol and lumisterol were detected. The applicant
provided information on three representative batches of the NF (UV-treated batches) and three
representative batches of the NF not exposed to UV treatment (untreated batches). The parameters
analysed were vitamin D2, ergosterol and lumisterol at a limit of detection of 0.5 lg/g and tachysterol
at a limit of detection of 1 lg/g.
In the UV-treated batches, the mean vitamin D2 content was 1,500 lg/g and the mean ergosterol
content was 8,747 lg/g. The untreated batches reported a mean vitamin D2 content of 0.72 lg/g and
a mean ergosterol content of 9,223 lg/g. The mean contents of the photoisomers in UV-treated
batches were lumisterol at concentrations of 206 lg/g of NF and tachysterol at 111 lg/g of NF.
The applicant indicated a content of vitamin D from the NF of 2.25 lg/100 g in food products other
than beverages that would result in intakes of lumisterol and tachysterol of 0.0005 lg/100 g and
0.0003 lg/100 g, respectively.
The NDA Panel noted that the tachysterol concentrations are lower than those reported in previous
EFSA Scientific Opinions on UV-treated novel foods (EFSA NDA Panel, 2014, 2015, 2016c). The exposure
to these compounds from the NF can therefore be considered not to be of toxicological relevance.
Table 3: Microbiological analysis of six batches of the NF
Microbiological
contaminants
Batch number and date of manufacture
Method of
analysis
Batch #1 Batch #2 Batch #3 Batch #4 Batch #5 Batch #6
Standard plate
count (CFU/g)
100 < 100 600 < 100 < 100 < 100 FDA (BAM) CH. 3
Yeast (CFU/g) < 10 < 10 < 10 < 10 < 10 10 FDA (BAM) CH. 18
Mould (CFU/g) 40 30 50 20 20 60 FDA (BAM) CH. 18
Salmonella spp. Conforms Conforms Conforms Conforms Conforms Conforms FDA (BAM) CH. 5
Staphylococcus
aureus (CFU/g)
< 10 < 10 < 10 < 10 < 10 < 10 FDA (BAM) CH. 12
Escherichia coli
(CFU/g)
< 10 < 3 < 3 < 3 < 3 < 3 FDA (BAM) CH. 4
Coliforms (CFU/g) < 10 < 3 < 3 < 3 < 3 < 3 FDA (BAM) CH. 4
Enterobacteriaceae
(CFU/g)
< 10 < 10 < 10 < 10 < 10 < 10 FDA (BAM) CH. 29
Listeria
monocytogenes
Conforms Conforms Conforms Conforms Conforms Conforms AOAC 2004.06
AOAC: Association of Official Analytical Chemists; CFU: colony forming units; NT: not tested; FDA (BAM): United States Food and
Drug Administration (Bacteriological Analytical Manual).
4 Regulation (EC) No 396/2005 of the European Parliament and of the Council of February 2005 on maximum residue levels of
pesticides in or on food and feed of plant and animal origin and amending Council Directive 91/414/EEC. OJ L 70, 16.3.2005, p. 1.
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The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
3.4.1. Stability
The applicant performed stability tests with five batches of the NF (stability of the bulk powder).
The tests were carried out at representative storage conditions (room temperature in sealed
polypropylene bags). The batches were analysed for vitamin D2 content. The results demonstrated
that the vitamin D2 content of the mushroom powder is stable for at least 3 years (intended shelf-life
of 2 years).
The applicant also provided stability studies of vitamin D2 mushroom powder as an ingredient in foods.
The NF was used in the production process of granola bars. Granola bars with and without the NF were
stored at room temperature for up to 3 months. The batches were analysed for vitamin D2 content. A
minor reduction of vitamin D2 was identified over time. The applicant noted that vitamin D is a liposoluble
vitamin and degradation over time due to oxidation is reported in the literature (EVM, 2003). The granola
bar samples with the added NF showed no difference in taste in comparison with the controls.
The applicant also tested the stability of the NF as an ingredient in soya drink. Results showed
variability (increase and decrease in vitamin D2 concentrations) and were therefore considered as not
suitable for the risk assessment.
The Panel considers that vitamin D2 from the NF is not expected to behave differently from vitamin
D2 from other production process.
The Panel considers that the data provided are sufficient with respect to the stability of the NF.
3.5. Specifications
The applicant describes the NF ingredient, i.e. vitamin D2 mushroom powder, as a slightly brown or tan
granular powder made from homogenised Agaricus bisporus mushrooms that have been exposed to UV
light.
The specifications for vitamin D2 mushroom powder as proposed by the applicant are reported in
Table 4. These specifications include physical and chemical parameters as well as chemical and
biological contaminants.
Upon request of EFSA, the applicant provided a maximum specification limit for vitamin D2 and
clarified the non-inclusion of the photoisomers tachysterol and lumisterol in the specifications (based
on the very low concentrations in the final product and low exposure through the NF, see Section 3.4).
Table 4: Specifications for vitamin D2 mushroom powder
Specification limit Method
Chemical parameters
Vitamin D2 1,000–1,300 lg/g
(a) HPLC
Moisture ≤ 10.0% AOAC 964.22
Ash ≤ 13.5% AOAC 945.46
Physical parameters
Particle size 100% through 80 mesh sieve –
Appearance Slightly brown or tan, granular powder –
Microbiological parameters
Standard plate count 5,000 CFU/g FDA (BAM) CH. 3
Yeast 100 CFU/g FDA (BAM) CH. 18
Mould 100 CFU/g FDA (BAM) CH. 18
Salmonella Absent in 25 g FDA (BAM) CH. 5
Staphylococcus aureus < 10 CFU/g FDA (BAM) CH. 12
Escherichia coli < 10 CFU/g FDA (BAM) CH. 4
Coliform < 10 CFU/g FDA (BAM) CH. 4
Enterobacteriaceae < 10 CFU/g FDA (BAM) CH. 29
Listeria monocytogenes Absent in 25 g AOAC 2004.06
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The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The source of the NF is the mushroom Agaricus bisporus. The applicant listed several publications
describing the history of the consumption, cultivation and production for human consumption of these
mushrooms within and outside the EU (FAO, 2004; OECD, 2007; FSAI, 2017).
In addition, according to the applicant, UV-treated Agaricus bisporus mushrooms have a history of
use in the EU (as they have been approved as a novel food ingredient since 2016) and in several non-
EU countries, including the United States, Canada and Australia (FSAI, 2017).
3.6.2. History of use of the NF
The NF, i.e. the powder from UV-treated Agaricus bisporusmushrooms, has no history of use in the EU.
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population for the consumption of the NF added to foods and beverages is the general
population.
The target population for the consumption of the NF added to foods for special medical purposes
(FSMPs) as defined in Regulation (EU) No 609/20135 is individuals above 1 year of age.
The target population proposed by the applicant for the consumption of the NF added to food
supplements is individuals above 7 months of age.
3.7.2. Proposed uses and use levels
The applicant intends to use the NF as an ingredient in a variety of foods and beverages as
indicated in Tables 5 and 6, in foods for special medical purposes as defined in Regulation (EU) No
609/2013 (excluding those intended for infants) and in food supplements. The use level of the NF in
food or beverages is determined by the applicant based on the vitamin D2 content per gram of NF
(1,000–1,300 lg vitamin D2/gram NF). The proposed levels of vitamin D2 from the NF are 2.25 lg/100
g for products other than beverages (excluding food supplements) and 1.125 lg/100 mL for beverages
(i.e. using the minimum specification for vitamin D content in the NF of 1,000 lg vitamin D2/gram NF).
Specification limit Method
Mycotoxins
Aflatoxins (sum of B1+B2+G1+G2) < 4 lg/kg AOAC 991.08
Heavy metals
Arsenic ≤ 0.3 mg/kg USP 730
Lead (as Pb) ≤ 0.5 mg/kg USP 730
Mercury ≤ 0.1 mg/kg USP 730
Cadmium < 0.5 mg/kg USP 730
Arsenic ≤ 0.3 mg/kg USP 730
AOAC: Association of Official Analytical Chemists; CFU: colony forming units; FDA (BAM): United States Food and Drug
Administration (Bacteriological Analytical Manual); HPLC : high-performance liquid chromatography; USP: United States
Pharmacopeia; –: no information available.
(a): Converted from International Units (IU) using the conversion factor of 0.025 lg = 1 IU stated in the EFSA Technical Report
on Dietary Reference Values for nutrients (EFSA, 2017).
5 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009 Text with EEA
relevance, OJ L 181, 29.6.2013, p. 35–56.
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The maximum proposed level of vitamin D2 as consumed using the maximum specification for vitamin D
content in the NF (i.e. 1,300 lg vitamin D2/gram NF) would result in an intake of 2.93 lg of vitamin D2/
100 g in foods and 1.46 lg of vitamin D2/100 mL for beverages.
The applicant also intends to market the NF as an ingredient in food supplement. In their initial
proposal, the applicant proposed to market the NF as food supplement at the maximum daily intake of
vitamin D2 of 15 lg for the general population excluding infants and children. Upon question from
EFSA, the applicant modified the use levels and proposed 15 lg/day for individuals above 1 year and
10 lg/day in food supplements for infants from 7 to 11 months. The applicant based those use levels
on the adequate intakes (AIs) for vitamin D specified by EFSA (EFSA, 2017). According to the
applicant, the NF used in food supplement would typically be taken as an alternative supplement
replacing other vitamin D2-containing supplements on the market.
The applicant also intends to market the NF as an ingredient in FSMPs (excluding those intended for
infants). For the adult population, the maximum intended use level in FSMPs is 15 lg vitamin D2/day.
Table 6: Proposed food categories based on the FoodEx2 classification system and use levels for
the NF in the EU
FoodEx2
code
FoodEx2
level
FoodEx2 name
Proposed maximum use
level of the NF (mg/100 g
or 100 mL), as
consumed(a)
A00CV 2 Breakfast cereals 2.25
A0BY0 3 Leavened bread and similar 2.25
A00BK 3 Yeast leavened pastry 2.25
A000K 2 Cereals and cereal primary derivatives 2.25
A007D 3 Pasta and similar products 2.25
A040M 3 Pastas and rice (or other cereal) – based dishes 2.25
A0BX9 2 Fruit/vegetable juices and nectars 1.125
A03BM 2 Concentrated or dehydrated fruit/vegetables juices 7.875(b)
A02LR 2 Milk and dairy products 2.25
A02MZ 3 Fermented milk or cream 2.25
A02NA 3 Sour cream products 2.25
Table 5: Proposed uses and use levels for the NF in the EU
Food groups Proposed food category name
Proposed maximum use
level of the NF (mg/100 g
or 100 mL), as consumed(a)
Breakfast cereals Breakfast cereals 2.25
Bakery products Yeast-leavened bread and pastries 2.25
Processed cereal food Grain products and pastas 2.25
Fruit juice and fruit/vegetable
blend beverages
Fruit and vegetable juices (incl. powders and
concentrates)
1.125
Dairy products Milk and dairy products (excl. fluid milks) 2.25/1.125 (beverages)
Cheese and cheese products Cheese (excl. cottage cheese, ricotta cheese,
and hard-grating cheeses)
2.25
Meal replacement Meal replacement bars and beverages, not
intended for weight control
2.25/1.125 (beverages)
Dairy analogues Dairy Imitates 2.25/1.125 (beverages)
Meat imitates Meat imitates 2.25
Soups and broths Soups (RTE and dry mixtures) 2.25
Vegetable snacks Extruded vegetable snacks 2.25
RTE: ready to eat.
(a): Proposed maximum use level of the NF per 100 g or 100 mL of each food category, considering the minimum specification
for vitamin D content in the NF of 1,000 µg vitamin D2/gram of NF.
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FoodEx2
code
FoodEx2
level
FoodEx2 name
Proposed maximum use
level of the NF (mg/100 g
or 100 mL), as
consumed(a)
A0C69 4 Fermented milk products 2.25
A02NE 4 Yoghurt 2.25
A02NQ 4 Yoghurt drinks 1.125
A02NR 4 Probiotic milk-like drinks 1.125
A0C69 4 Fermented milk products 2.25
A02NT 5 Traditional sour milk products 2.25
A02NV 5 Kefir 1.125
A02NY 5 Traditional Nordic fermented milks 1.125
A02PC 5 Flavoured traditional sour milk products 2.25
A02PD 3 Milk and dairy powders and concentrates 2.25
A02PE 3 Milk and dairy concentrate 2.25
A02PH 4 Milk and dairy powders 22.5(c)
A02PJ 4 Milk powder 22.5(c)
A02PM 4 Cream powder 92.25(d)
A02PN 4 Whey powder 22.5(c)
A02MP 4 Flavoured milks 1.125
A02MK 3 Cream and cream products 2.25
A0EZB 3 Whey 2.25
A02MV 3 Buttermilk 2.25
A02PT 2 Dairy dessert and similar 2.25
A02QE 3 Cheese 2.25
A02QF 4 Fresh uncured cheese 2.25
A02QH 4 Mascarpone 2.25
A02QJ 4 Mozzarella 2.25
A02QK 4 Quark 2.25
AS04NV 4 Miscellaneous fresh uncured cheeses 2.25
A0CRN 4 Cheese curd 2.25
A02RA 4 Brined cheese (feta-type and similar) 2.25
A02RB 4 Soft brined cheese (feta-type) 2.25
A02RG 4 Ripened cheese 2.25
A02RH 4 Soft – ripened cheese 2.25
A031A 3 Processed cheese and spreads 2.25
A03RS 4 Food for weight reduction(e) 2.25(f)
A03RV 4 Single meal replacement for weight reduction 2.25
A03TH 4 Milk imitates 1.125
A03TQ 4 Dairy imitates other than milks 2.25
A0BXC 4 Dairy imitates 2.25
A03TE 2 Meat imitates 2.25
A0B9J 3 Soups, dry mixture, uncooked 20.25(g)
A041L 3 Soups, ready-to-eat 2.25
A0EQV 4 Vegetable snacks, puffs/curls-type extruded snack 2.25
A011L 5 Potato crisps or sticks 2.25
NF: novel food.
(a): The use level of vitamin D2 mushroom powder is determined based on maximum 1,000 lg vitamin D2/gram of mushroom
powder.
(b): Adjusted for being present in concentrated or dehydrated form; reconstitution factor of 7 (based on available products on
the market).
(c): Adjusted for being present in powder form; reconstitution factor of 10 (based on available products on the market).
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3.7.3. Anticipated intake of the NF
Anticipated intake of the NF from the proposed food uses, as an ingredient in foods and
beverages
The applicant provided estimates of the anticipated daily intake of the NF for each food category
indicated in Table 6, based on the summary statistics from the EFSA Comprehensive European Food
Consumption Database.6
EFSA performed an additional intake assessment of the NF based on the individual consumption
data from the EFSA Comprehensive Food Consumption Database (EFSA, 2011). For this estimation,
EFSA considered the food categories and the maximum use levels proposed by the applicant in Table 6.
The ranges of the estimated daily intake of the NF (i.e. lowest and highest means and 95th
percentiles among surveys covered by the EFSA Database), from foods to which the NF is added, are
presented in Table 7 (on a mg/kg body weight (bw) per day basis). The estimated daily intake of the
NF for each population group from each EU dietary survey is available in the excel file annexed to this
scientific opinion (under supporting information).
As stated in Section 3.5 on Specifications, the NF contains 1,000–1,300 lg vitamin D2/g NF.
Therefore, based on estimated daily intakes of the NF and using a maximum content of 1,300 lg
vitamin D2/g NF, estimated daily intakes of vitamin D2 calculated both in absolute values (lg/day) and
on a per body weight basis (lg/kg bw per day) are reported in Table 8.
(d): Adjusted for being present in powder form – assumed to be used as coffee whitener; reconstitution factor of 41 (based on
available products on the market).
(e): While the food use name includes the term ‘for weight reduction’, these are representative of use in the general population
and not intended to be used for special dietary purposes.
(f): Unable to distinguish between food products and beverages. Therefore, the higher use level (i.e., 2.25 for food products)
was applied in this category.
(g): Adjusted for being present in powder form; reconstitution factor of 9 (based on available products on the market).
Table 7: Anticipated daily intake of the NF on a mg/kg bw per day basis: lowest and highest
means and 95th percentiles anticipated daily intake of the NF among the EU surveys in the
EFSA Comprehensive European Food Consumption Database (calculated by EFSA)
Population group
Number of
EU surveys
Estimated intake of the NF as food/beverage ingredient
(mg/kg bw per day)
Range of means
(minimum and
maximum) across
EU dietary surveys
Range of 95th percentile
(minimum and maximum) across
EU dietary surveys
Infants (≤ 11 months) 11 0.06–0.52 0.29–1.87
Young children7
(12–35 months)
14 0.34–0.67 0.65–1.28
Children (3–9 years) 19 0.26–0.50 0.49–0.97
Adolescents (10–17
years)
18 0.13–0.22 0.26–0.45
Adults (18–64 years) 19 0.08–0.15 0.15–0.31
Pregnant women 2 0.10–0.12 0.18–0.21
Lactating women 2 0.12–0.14 0.22–0.24
Elderly (65–74 years) 18 0.07–0.14 0.13–0.32
Very elderly (≥ 75
years)
14 0.07–0.14 0.13–0.27
bw: body weight; NF: novel food.
6 https://www.efsa.europa.eu/en/food-consumption/comprehensive-database
7 Referred as toddlers in the EFSA food consumption comprehensive database (EFSA, 2011).
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The Panel notes that the intake estimates for vitamin D2 from the foods added with the NF are
based on conservative assumptions, which are that the NF always contains the upper specification limit
of vitamin D (i.e. 1,300 lg/g NF) and that all proposed food items consumed by an individual actually
contain the NF at the maximum proposed use levels.
3.7.4. Combined vitamin D intake from the NF and other sources
The potential combined intake of vitamin D from the NF (vitamin D2) and other sources (vitamin D2
or D3) is estimated by summing the contribution to vitamin D intake from the NF as estimated by EFSA
(Table 8) and the high vitamin D intakes from other food sources as reported by the EFSA NDA
Panel in 2012 based on a literature review (EFSA NDA Panel, 2012).
In this Opinion from 2012, the highest 95th percentile (P95) dietary intake across surveys in adults
was 16 lg vitamin D/day. The P95 exposure from the background diet alone was not available for all
children in the EFSA opinion from 2012, and as a substitute, the highest mean intakes across the
covered surveys for each age category of children were used. The highest mean intakes were 5.6 lg/
day in younger children (1–5 years), 2.7 lg/day in older children (4–13 years) and 4.0 lg/day in
adolescents (11–18 years). The P95 intakes from the sum of food and supplements were however
available for children (up to 15 lg/day) and adolescents (up to 8 lg/day) in this previous opinion of
the EFSA NDA Panel (2012) and were also used in the present calculations, but without it to the intake
of vitamin D2 from the NF as food supplement.
Table 9 provides an overview of the exposure to vitamin D from different sources separately and
combined, and a comparison of the total estimated intake with the tolerable upper intake levels (ULs)
established for young children, children, adolescents and adults.
Table 8: Anticipated P95 of daily intake of the vitamin D2 from the NF as ingredient in foods and
beverages considering a vitamin D2 concentration in the NF of 1,300 lg/g (calculated by
EFSA)
Anticipated P95 daily intake of vitamin D2 from the NF as
ingredient in foods and beverages
Population class (lg/kg bw per day) (lg/day)(a)
Infants (≤ 11 months) 2.43 12.2
Young children (12– 35 months) 1.66 19.9
Other children (3–9 years) 1.26 28.9
Adolescents (10–17 years) 0.59 25.3
Adults (18–64 years) 0.40 28.1
Pregnant women 0.27 19.2
Lactating women 0.31 21.9
Elderly (65–74 years) 0.42 29.2
Very elderly (≥ 75 years) 0.36 25.0
bw: body weight; NF: novel food.
(a): Based on default body weights as given for the different age groups as described in (EFSA Scientific Committee, 2012).
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The Panel notes that estimates for combined intake of vitamin D2 from the NF (added to the foods,
beverages and food supplements) plus estimated intake of vitamin D from the background diet result
in overall vitamin D intakes of 44, 59, 60 and 56 lg/day for adolescents, adults, elderly and very
elderly, respectively.
For pregnant and lactating women, such combined intake estimates result in values of 50 and 53
lg/day, respectively.
Those intake estimates are below the UL of 100 lg/day (EFSA NDA Panel, 2012) for each of these
population groups.
In children, estimating the combined intake of vitamin D2 from the NF (19.9 and 28.9 lg/day for
young children and other children, respectively) plus intake of vitamin D from other dietary sources
(including 15 lg/day from the NF when used in food supplements) results in vitamin D intakes of 40
and 47 lg/day for young children and other children, respectively. The Panel notes that those
estimated combined intakes are below the upper level (UL) established by EFSA for children aged 1–10
years (50 lg/day) (EFSA NDA Panel, 2012).
For infants aged from 4 to 12 months, data on vitamin D intake were estimated by EFSA using
composition data from the EFSA nutrient composition database and individual consumption data from
national surveys from 6 European countries (EFSA NDA Panel, 2018). In addition to the vitamin D
intake provided by infant formula (IF) or follow-on formula (FoF), the vitamin D intake from
Table 9: Estimated daily intakes of vitamin D (lg/day) from the different sources and combined
intake of vitamin D compared with ULs per population group > 1 year
Population
group
1) Intake of
vitamin D from
foods in the
background diet
(P95 intake for
adults and
highest mean
intakes for
children and
adolescents)
EFSA NDA
Panel (2012)
2) Highest P95
estimated intake
of vitamin D2
from the NF as
an ingredient in
foods and
beverage (from
Table 8)
3) Intake of
vitamin D2
from the NF as
food
supplements
4) Combined
intake of
vitamin D from
1+2+3
(background
diet, NF as
ingredient, NF
as supplement
if applicable)
UL
(lg/day) EFSA
NDA Panel
(2012)
Young children
(12–35
months)
5.6(a)
15(b)
19.9
19.9
15
–
40.5
34.9(c)
50
Other children
(3–9 years)
2.7(a)
15(b)
28.9
28.9
15
–
46.6
43.9(c)
50
Adolescents
(10–17 years)
4(a)
8(b)
25.3
25.3
15
–
44.3
33.3(c)
100
Adults
(18–64 years)
16 28.1 15 59.1 100
Pregnant
women
16 19.2 15 50.2 100
Lactating
women
16 21.9 15 52.9 100
Elderly
(65–74 years)
16 29.2 15 60.2 100
Very elderly
(≥ 75 years)
16 25.0 15 56.0 100
UL: tolerable upper intake level; NF: novel food.
(a): Maximum mean/median intake of vitamin D from foods only. Data collected from different surveys/studies (EFSA NDA Panel,
2012).
(b): Combined vitamin D intake from foods and supplements; vitamin D intake from high consumers (90th or 95th percentile
depending on surveys) in infants, children and adolescents (EFSA NDA Panel, 2012).
(c): Dietary intake of vitamin D included in foods and food supplements (EFSA NDA Panel, 2012). In order to avoid
overestimation of vitamin D intake, the maximum intake of vitamin D from the total diet (combined intake, column 5) does
not include the contribution of the vitamin D from the NF used as ingredient in food supplements.
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complementary feeding was considered, including foods naturally containing vitamin D and foods
fortified with vitamin D, but intake of vitamin D via supplements was not considered.
For this age group, P95 intakes for vitamin D ranged across the surveys from 13.2 to 16.9 lg/day
in formula consumers8 not consuming (voluntarily) fortified foods. For non-formula consumers that
were also not consuming (voluntarily) fortified foods, the P95 vitamin D intake from the diet ranged
between 0.7 and 2.8 lg/day (EFSA NDA Panel, 2018).
For formula consumers8 consuming also fortified foods, the P95 vitamin D intake ranged from 15.2
to 22.2 lg/day. For non-formula consumers, the P95 intake from diet including fortified foods ranged
from 1.6 to 10 lg/day (based on scenario 6 from Annex B of EFSA NDA Panel, 2018).
For infants, the estimated P95 intake of vitamin D2 from the NF as an ingredient in foods is 12.2
lg/day (see Table 8). The addition of this amount to the highest P95 vitamin D intake of formula
consumers not consuming fortified foods (16.9 lg/day) results in a combined intake of 29.1 lg/day
(for comparison, the highest P95 intake of vitamin D in formula consumers consuming also fortified
foods was 22.2 lg/day, according to EFSA, 2018). This estimated combined intake of 29.1 lg/day can
be considered an overestimation as highest formula consumers can be assumed not to be also highest
consumers of fortified foods including foods with the added NF. The Panel notes that this estimated
combined intake of 29.1 lg/day is below the UL of 35 lg/day for infants aged 6 to less than 12
months established by EFSA (EFSA NDA Panel, 2018).
The addition of 10 lg/day of vitamin D2 from the NF used as an ingredient in supplement (which
the applicant intends to market for infants aged from 7 to 12 months) to the (most likely
overestimated) intake of 29.1 lg/day would result in an intake of 39.1 lg/day and thus would exceed
the UL.
When adding 10 lg/day to the previously estimated intake of 22.2 lg/day (as calculated by EFSA
NDA Panel, 2018), the combined estimated intake of vitamin D from formula, fortified foods and
supplements containing the NF amounts to 32.2 lg vitamin D/day and thus would be below the UL for
vitamin D of 35 lg/day established by EFSA in 2018.
3.7.5. Estimate of exposure to undesirable substances in mushrooms
The undesirable toxicological substances in mushrooms have been described by the Consensus
document on compositional considerations for new varieties of the cultivated mushrooms Agaricus
bisporus (OECD, 2007). Agaritine (b-N-[c-L-(+)-glutamyl]-4-hydroxymethylphenyl-hydrazine) is a
natural occurring phenylhydrazine derivative found in mushrooms. Agaritine ranges were reported by
OECD between 80 and 1,730 mg/kg fresh weight of mushrooms (OECD, 2007).
As explained in Section 3.3 Production process, the NF is produced from the fresh cultivated
Agaricus bisporus mushrooms. Based on the NF production yield from fresh mushroom and on the
highest estimated intakes provided by the applicant, and considering that a food portion size of
mushrooms is approximately 70 g (FSA, 2002), the estimated maximum additional intake due to the
NF would correspond to less than 1.3% of a single serving of mushrooms.
As reported in Section 3.4 Compositional data, the UV processing inducing the conversion of
ergosterol to vitamin D2 is accompanied by isomerisations resulting in tachysterol and lumisterol. The
applicant indicated a maximum use level of the NF of 2.25 lg/100 g for food products other than
beverages that would result in intakes of lumisterol and tachysterol of 0.0005 lg/100 g and 0.0003
lg/100 g, respectively. The Panel also noted that the tachysterol concentrations are lower than those
reported in previous EFSA Scientific Opinions on UV-treated novel foods, which did not give rise to
safety concerns (EFSA NDA Panel 2014, 2015, 2016c).
The Panel considers that there is no concern with respect to the exposure to undesirable
substances from mushrooms (i.e. agaritine) and from the NF production process (lumisterol and
tachysterol) from the consumption of NF at the proposed uses.
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant has not provided specific ADME studies for the NF, but has submitted publicly
available animal and human studies that suggest that vitamin D2 from powder from UV-irradiated
mushrooms is bioavailable, as dose-related increase in serum concentrations of 25(OH)D2 are observed
upon its oral consumption. Some of these studies have been carried out with material similar to the NF
8 Containing maximum regulated vitamin D content (2.5 µg/100 kcal for IF; 3.0 µg/100 kcal for FoF), in accordance with
Commission Delegated Regulation (EU)2019/828 amending Delegated Regulation (EU) 2016/127.
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(i.e. powder from UV-radiated Agaricus bisporus mushrooms). These studies (Bennett et al., 2013;
Calvo et al., 2013; Koyyalamudi et al., 2009; Stephensen et al., 2012; Shanley et al., 2014; Stepien
et al., 2013) are presented in Appendices A and B.
Results from a meta-analysis on randomised clinical trials (RCTs) with UV-exposed and vitamin D2-
enriched mushrooms suggest an effect of their consumption on serum total 25(OH)D concentration
when the mean baseline vitamin D status of the participants is inadequate [serum 25(OH)D < 50
nmol/L], but no effect when vitamin D status is ‘high’ [mean baseline 25(OH)D: 81.5 nmol/L]], due to
a reduction in serum 25(OH)D3 that accompanies the increase in serum 25(OH)D2 (Cashman et al.,
2016).
Studies comparing the effects of vitamin D2 and D3 supplementation on serum 25(OH)D
concentrations in a small number of infants, showed no statistically significant differences between the
effects of the two vitamin forms (Gordon et al., 2008; Gallo et al., 2013).
3.9. Nutritional information
The applicant refers to a publication by Simon et al. (2011) where the vitamin content of Agaricus
bisporus mushrooms exposed to UV light was investigated. In this study, the nutritional content of the
mushrooms (including macronutrients, fatty acids, amino acids, water-soluble vitamins) remained
unchanged by the UV treatment, with the exception of the intended increase in the vitamin D2
content.
The Panel notes that the intakes of vitamin D2 in high consumers of foods and beverages fortified
with the NF are above the AIs for all age groups set by the NDA Panel of EFSA (EFSA NDA Panel,
2016b). However, together with the intake of vitamin D from background diet and possible intake of
the NF supplement (see Section 3.7.4), the total daily vitamin D intakes do not exceed the ULs set for
children aged 1–10 years (50 lg/day), adolescents and adults (100 lg/day) (EFSA NDA Panel, 2012).
For infants, the Panel notes that, based on the intake assessment for vitamin D in infants (EFSA
NDA Panel, 2018), combined highest P95 intakes of vitamin D from background diet, including IF
and/or FoF and fortified foods and foods in which the NF would be added (see Section 3.7.4), do
not exceed the ULs set for infants aged 0–6 months at 25 lg/day and for infants 6–12 months at
35 lg/day. With regard to infants aged ≥ 7 to 12 months, the Panel notes that the additional intake of 10
lg/day of vitamin D2 from the NF used as an ingredient in food supplements, in high consumers of
vitamin D (from background diet, including IF and/or FoF and fortified foods), would result in a total
vitamin D intake of 32 lg/day, close to, but not exceeding the UL of 35 lg/day.
Given the assumption that infants who are high consumers of IF and/or FoF may also be high
consumers of foods fortified with the NF, then some infants aged 0–6 months may be at risk of
exceeding the UL for vitamin D (25 lg/day). For infants aged 7–12 months, using the (most likely
overestimated) intake of 29.1 lg vitamin D/day, the additional intake of 10 lg/day could result in
exceeding the UL of 35 lg/day. However, the Panel considers this scenario unlikely as complementary
feeding in high consumers of IF and/or FoF may be limited.
Considering that daily oral supplementation of 10 lg vitamin D is generally recommended for all
infants during the first year of life starting from birth onwards (ESPGHAN Committee on Nutrition,
Braegger et al., 2013 cited in EFSA NDA Panel, 2016b), there is a potential risk of approaching or
exceeding the UL for vitamin D in infants. However, this is a general issue related to the combined
consumption of vitamin D via fortified foods and supplements and does not specifically concern the NF
of this application.
The Panel considers that consumption of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
No specific toxicity studies on the NF have been submitted by the applicant. For previous scientific
opinions on similar NFs (on UV-treated baker’s yeast, bread or milk), no toxicological studies were
considered necessary (EFSA NDA Panel, 2014, 2015, 2016c).
3.10.1. Genotoxicity
No specific studies on genotoxicity of the NF were provided. The Panel notes that given the source,
nature, and the intended use of the NF, genotoxicity studies are not required.
Safety of vitamin D2 mushroom powder
www.efsa.europa.eu/efsajournal 16 EFSA Journal 2020;18(1):5948
3.10.2. Subacute, subchronic and chronic toxicity
No specific studies with the NF have been carried out, but several publicly available animal studies
with material similar to the NF have been submitted by the applicant. The studies in which powder
from UV-treated Agaricus bisporus was tested are summarised in Appendix A (subacute and chronic
toxicity studies).
3.10.3. Carcinogenicity
No studies on carcinogenicity were provided. The Panel notes that given the source, nature, and
the intended use of the NF carcinogenicity studies are not required.
3.10.4. Reproductive and developmental toxicity
No studies on reproductive and developmental toxicity were provided. The Panel notes that given
the source, nature, and the intended use of the NF reproductive and developmental toxicity studies
are not required.
3.10.5. Human data
No specific studies on the NF were provided, but the applicant provided several publicly available
human intervention studies where material similar to the NF has been tested. The studies in which
powder from UV-treated Agaricus bisporus was investigated are summarised in Appendix B.
The studies presented in Annex B show that consumption of powder from UV-treated mushrooms
from 4 to 6 weeks, significantly increases serum concentrations of 25(OH)D2 and total 25(OH)D in
humans, while no other changes in blood parameters or adverse effects (see Appendix B for individual
parameters) were observed. The doses of vitamin D2 (contained in the mushroom powders) given ranged
between 15 and 17.1 lg/day. The Panel notes that the estimated ‘worst case’ vitamin D2 intakes in
humans, combining intake of vitamin D2 from the NF together with other dietary sources (see
Section 3.7.4 ‘Combined vitamin D intake from the NF and other sources’ of this opinion), were higher
(ranging from 40.5 to 60.2 lg/day in the different age groups) than these doses. Therefore, the human
studies presented are of limited value for the assessment of potential effects on human health of the NF.
3.11. Allergenicity
The applicant refers to the conclusion by the Food Safety Authority of Ireland (FSAI) in 2017
regarding UV-treated mushrooms approved as novel food, i.e. that ‘allergenicity or other food
hypersensitivities associated with Agaricus bisporus are rare and there is no reason to believe that the
additional UV treatment will alter that risk’ (FSAI, 2017). The Panel concurs with this view.
4. Discussion
The NF is produced from Agaricus bisporus mushrooms that have been exposed to UV light to
induce the conversion of provitamin D2 (ergosterol) to vitamin D2 (ergocalciferol). The NF contains
levels of vitamin D provided by vitamin D2 in the range of 1,000–1,300 lg/g.
The information provided on the manufacturing process, composition and specifications of the NF
does not raise safety concerns.
The applicant intends to add the NF in a variety of foods and beverages, including food for special
medical purposes (excluding those intended for infants) and food supplements. The target population
is the general population except for food supplements, for which the target population is individuals
above seven months of age.
The conservative highest vitamin D estimates for combined intake of vitamin D2 from the NF together
with intake from other dietary sources were below the upper levels for vitamin D as established previously
by the NDA Panel for ‘Young children’ and ‘Other children’, ‘Adolescents’, ‘Adults’, ‘Pregnant women’,
‘Lactating women’, ‘Elderly’ and ‘Very elderly’ (NDA Panel, 2012) and ‘Infants’ (NDA Panel, 2018).
The Panel notes that vitamin D intake in high consumers of IF and or FoF with the maximum
regulated content of vitamin D consuming also fortified foods as calculated by EFSA (NDA Panel, 2018)
does not result in exceeding the ULs set for infants aged 0–6 months or ≥ 7–12 months.
Given the assumption that infants aged 0–6 months who are high consumers of IF and/or FoF may
also be high consumers of foods fortified with the NF, some infants may be at risk of exceeding the UL for
vitamin D (25 lg/day). For infants aged 7–12 months, using the (most likely overestimated) intake of
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29.1 lg vitamin D/day, the additional intake of 10 lg/day could result in exceeding the UL of 35 lg/day.
However, the Panel considers this scenario unlikely as complementary feeding in high consumers of IF
and/or FoF may be limited.
Considering that daily oral supplementation of 10 lg vitamin D is generally recommended for all
infants during the first year of life starting from birth onwards (ESPGHAN Committee on Nutrition,
Braegger et al., 2013 cited in EFSA NDA Panel, 2016b), there is a potential risk of approaching or
exceeding the UL for vitamin D in infants. However, this is a general issue related to the combined
consumption of vitamin D via fortified foods and supplements and does not specifically concern the NF
of this application.
5. Conclusions
The Panel concludes that the NF, vitamin D2 mushroom powder, is safe under the proposed
conditions of use. The target population is the general population, except for food supplements for
which the target population is individuals above 7 months of age.
The Panel concludes that the NF, used as an ingredient, is safe for the general population at the
proposed condition of use in foods and beverages.
The Panel concludes that the NF is safe for the adult population at intake levels up to 15 lg vitamin
D2/day used in foods for special medical purposes.
The Panel concludes that the NF, used as a food supplement, is safe for individuals above 1 year at
a level up to 15 lg vitamin D2/day.
The Panel, however, notes that the UL for infants may be exceeded in high consumers of IF and/or
FoF that may also be high consumers of foods fortified with the NF, and infants aged 7–12 months
consuming the food supplement containing 10 lg of vitamin D. However, the Panel considers this
scenario unlikely as complementary feeding in high consumers of IF and/or FoF may be limited.
Considering that daily oral supplementation of 10 lg vitamin D is generally recommended for all infants
during the first year of life starting from birth onwards (ESPGHAN Committee on Nutrition, Braegger et al.,
2013 cited in EFSA NDA Panel, 2016b), there is a potential risk of approaching or exceeding the UL for
vitamin D in infants. However, this is a general issue related to the combined consumption of vitamin D via
fortified foods and supplements and does not specifically concern the NF of this application.
The Panel could not have reached the conclusions on the safety of the NF under the proposed
conditions of use without the following data claimed as proprietary by the applicant:
• Annex I: Raw materials and processing aids
• Annex II : Certificates of Analysis and batch data
• Annex III: Stability reports.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of vitamin D2 mushroom powder as a NF. Ref.
Ares (2018)5350698, dated 18 October 2018.
2) On 18 October 2018, EFSA received a valid application from the European Commission on
vitamin D2 mushroom powder as NF, which was submitted by Oakshire Naturals, LP, and the
scientific evaluation procedure started.
3) On 30 January, 4 June and 28 October 2019, EFSA requested the applicant to provide
additional information to accompany the application and the scientific evaluation was
suspended.
4) On 4 April, 21 August, 12 and 26 November 2019, additional information was provided by
the applicant and the scientific evaluation was restarted.
5) During its meeting on 28 November 2019, the NDA Panel, having evaluated the data,
adopted a scientific opinion on the safety of vitamin D2 mushroom powder as a novel food
pursuant to Regulation (EU) 2015/2283.
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Abbreviations
24,25(OH)2D3 24,25-hydroxycholecalciferol
25(OH)D2 25-hydroxyvitamin D2
25(OH)D3 25-hydroxyvitamin D3
ADME absorption, distribution, metabolism and excretion
AOAC Association of Official Analytical Chemists
AI adequate intake
AST aspartate aminotransferase
BMI body mass index
BP blood pressure
bw body weight
CAS Chemicals Abstracts Service
CPK creatine phosphokinase
FoF follow-on formula
FSAI Food safety Authority of Ireland
FSMA Food Safety Modernization Act
GAP Good Agricultural Practices
HACCP Hazard Analysis Critical Control Points
HDL high-density lipoprotein
HPLC high-performance liquid chromatography
hsCRP high-sensitivity C-reactive protein
IF Infant formula
IL-6 interleukin 6
iPTH intact parathyroid hormone
IU International Units
LDH lactate dehydrogenase
LDL low-density lipoprotein
MB myoglobin
ML maximum levels
ND not detected
NDA Nutrition, Novel Foods and Food Allergens
NEFA non-esterified fatty acids
NF novel food
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NFI novel food ingredient
OECD Organisation for Economic Cooperation and Development
PAI-1 plasminogen activator inhibitor-1
PTH parathyroid hormone
RCT randomised clinical trial
TAG triacylglycerol
TNF-a tumour necrosis factor-a
UL tolerable upper intake level
USP United States Pharmacopeia
UV ultraviolet
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Appendix A – Subacute and chronic toxicity animal studies with powder of UV-radiated Agaricus bisporus
Species (strain), sex;
number of animals
Route of
administration/
duration
Test item and dose groups Parameters evaluated Results Reference
Mouse (transgenic
APPswe/PS1dE9 and
wild-type); M; 10–13
per group
Oral (diet);
7 months
Wild-type groups: control (basal diet); 5% UV-C-
irradiated Agaricus bisporus mushroom powder (54
IU vitamin D2/kg or 1.35 lg vitamin D2/kg feed)
Transgenic groups: control (basal diet); 5% UV-C-
irradiated Agaricus bisporus mushroom powder(54
IU vitamin D2/kg or 1.35 lg vitamin D2/kg feed).
These feed concentrations correspond to a dose of
around 0.18 lg vitamin D2/kg bw per day
(a)
Clinical signs, bw, Morris
water maze, Barnes maze,
Y-maze, liver function
biomarkers (plasma total
protein, albumin, globulin),
cholesterol, calcium, 25(OH)
D2, 25(OH)D3, b-amyloid
load (Ab40, Ab42) in plasma
and brain,
immunohistochemistry
(brain)
No reported clinical signs or
differences in bw gain
between groups. No
differences in liver function
biomarkers or cholesterol
between groups. ↑ 25(OH)D2
and 25(OH)D3, ↑learning and
memory and ↓ b-amyloid
plaque load in brain of treated
animals
Bennett
et al.
(2013)
Rat (SD); F; 6 per
group
Oral (diet);
10 weeks
Control (basal diet); control (vitamin D-deficient
diet); Control (non-irradiated Agaricus bisporus
mushroom powder); 2.5 or 5% UV-B-irradiated
Agaricus bisporus mushroom powder corresponding
to 300 or 600 IU or 7.5 or 15 lg vitamin D2/day.
These correspond to doses of around 37.5 or 75 lg
vitamin D2/kg bw per day
(a)
Bw, femur density, plasma
25(OH)D2 and
histopathology (kidney, liver,
and spleen)
No reported clinical signs or
differences in bw between
groups. ↑ 25(OH)D2 in treated
animals
No test item-related
histopathological findings
Calvo et al.
(2013)
Rat (SD); M; 5 per
group
Oral (gavage);
3 weeks
Control (non-irradiated Agaricus bisporus
mushrooms) 50, 100 or 200 mg/kg bw per day UV-
C-irradiated Agaricus bisporus mushroom powder.
At a concentration of 17.6 lg vitamin D2/g (as
reported in the paper), this corresponds to doses of
0.88, 1.76 and 3.52 lg vitamin D2/kg bw per day
bw, food intake and plasma
25(OH)D2
No reported clinical signs or
effects on bw or food intake.↑
25(OH)D2 in animals given
vitamin D2 mushroom powder
(all doses)
Koyyalamudi
et al.
(2009)
25(OH)D2: 25-hydroxyvitamin D2; 25(OH)D3: 25-hydroxyvitamin D3; bw: body weight; F: females; IU: International Units; M: males; SD: Sprague–Dawley; UV: ultraviolet.
(a): Because doses were not reported, concentrations in feed were converted to doses following EFSA guidance (EFSA Scientific Committee, 2012).
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Appendix B – Human intervention studies with powder of UV-radiated Agaricus bisporus
Study design Duration Tested material Dosage Parameters investigated Results Reference
Double-blinded,
randomised, placebo-
controlled trial; 38
healthy adults (9–10
per group)
6 weeks UV-B-irradiated
Agaricus bisporus
mushroom powder
(10–25 lg/serving)
Placebo control: untreated mushrooms
providing 34 IU (or 0.85 lg) vitamin D2/day;
Test group 1: UV-B-irradiated mushroom
powder (352 IU (8.8 lg) vitamin D2/day);
Test Group 2: UV-B-irradiated mushroom
powder (684 IU (17.1 lg) vitamin D2/day);
Supplement Group: purified ergocalciferol +
untreated mushrooms (total of 1,128 IU
(28.2 lg) vitamin D2/day)
Serum 25(OH)D2, 25(OH)D3;
24,25(OH)2D3
No reported
adverse effects. ↑
25(OH)D2 and ↓ 25
(OH)D3 in Test
groups 1, 2 and
supplement group
Stephensen
et al. (2012)
Double-blinded,
randomised, placebo-
controlled trial; 33
vitamin D insufficient
highschool athletes
(16–17 per group)
6 weeks UV-B-irradiated-
Agaricus bisporus
mushroom powder
Placebo control: Untreated mushroom
powder (ND vitamin D2); Test Group: UV-B-
irradiated mushroom powder (600 IU (15 lg)
vitamin D2/day)
Serum total 25(OH)D, 25
(OH)D2, 25(OH)D3, LDH,
AST, CPK, MB
No reported
adverse effects. ↑
25(OH)D2, ↓ 25
(OH)D3 and ↑ total
25(OH)D in test
group
No effects on the
blood parameters
investigated
Shanely et al.
(2014)
Double-blinded,
randomised, placebo-
controlled trial 90
healthy adults (22 per
group)
4 weeks UV-B-irradiated
Agaricus bisporus
mushroom powder
Study 1: Placebo control: Untreated
mushroom powder (ND vitamin D2)
Test Group: UV-irradiated mushroom powder
(600 IU (15 lg) vitamin D2/day)
Study 2: Placebo control: placebo capsule
(ND vitamin D3); Supplement Group: vitamin
D3 capsule (600 IU (15 lg) vitamin D3/day)
Bw, height, BMI, BP (systolic
and diastolic)
Serum total 25(OH)D, 25
(OH)D2, 25(OH)D3, glucose,
insulin, HR, HOMA-IR, C-
peptide, TAG, cholesterol
(total, HDL, and LDL), NEFA,
PTH, calcium, adiponectin,
ferritin, leptin, resistin, sCRP,
TNF-a, IL-6, PAI-1
No reported
adverse effects. ↑
25(OH)D2 in test
group and ↑ 25
(OH)D3 in vitamin
D3 supplement
group
No effects on the
blood parameters
investigated
Stepien et al.
(2013)
24,25(OH)2D3: 24,25-hydroxycholecalciferol; 25(OH)D2: 25-hydroxyvitamin D2; 25(OH)D3: 25-hydroxyvitamin D3; AST: aspartate aminotransferase; BMI: body mass index; BP: blood pressure; bw:
body weight; CPK: creatine phosphokinase; HDL: high-density lipoprotein; hsCRP: high-sensitivity C-reactive protein; IL-6: interleukin 6; iPTH: intact parathyroid hormone; IU: International Units;
LDH: lactate dehydrogenase; LDL: low-density lipoprotein; MB: myoglobin; ND: not detected; NEFA: non-esterified fatty acids; PAI-1: plasminogen activator inhibitor-1; PTH: parathyroid hormone;
TAG: triacylglycerol; TNF-a: tumour necrosis factor-a; UV: ultraviolet.
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